OS Essentials Hybrid CBD100

Name: OS Essentials Hybrid CBD100
SKU: 13565
Availability: InStock

Genetic:

Hybrid

Excipient:

Medium-chain triglycerides (MCT)

Potency:

100 mg/mL CBD

Route of administration:

Oral

Onset of action:

60-180 minutes

Durantion of action:

6 and 8 hours

Indication

-Chronic pain
-Anxiety
-Schizophrenia
-Other Indications as Clinically Justified

References

1. Therapeutic Goods Administration (TGA). “Guidance for the use of medicinal cannabis in the treatment of chronic non-cancer pain in Australia”. January 25, 2024. https://www.tga.gov.au/medicinal-cannabis-guidance-documents.
2.Bergamaschi MM, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-26.

Titration and dosing

THESE TITRATION MODELS SERVE AS AN EXAMPLE AND MUST BE ADAPTED TO EACH PATIENT

Days	Morning dose (mL of oral solution)	Evening dose (mL of oral solution)	Total daily dose (mL of oral solution)	Total CBD daily dose (mg)
1-2	0.25	0.25	0.5	50
3-4	0.5	0.5	1	100
5-6	0.75	0.75	1.5	150
7-8	1	1	2	200
9-10	1.5	1.5	3	300

Titration scheme and practical dosing recommendations:

The patient should take the minimum dose that provides effective symptom relief with tolerable side effects.
The titration should be conservative, done with increments of 2.5 mg THC every 2 days (or with increments of 1.25 mg THC for fragile patients).

The dosage protocol can be adjusted according to the patient’s profile. Increase dose as necessary and as tolerated, up to 15 mg of THC. Daily THC doses exceeding 20–30 mg may elevate the risk of adverse events or lead to the development of tolerance without improving efficacy.1 Maximum recommended daily THC dose: 40 mg.

*Ideally, the administration should start with an evening dose to limit adverse events and encourage the development of tolerance.

References

1. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. EwoRean Journal of Internal Medicine. 2018; 49: 12-19.

Terpenes and Minor Cannabinoids profile

Not applicable for this product

Consumer Medicine Information